Cytokinetics, Incorporated (CYTK) — Stock Valuation & Research

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection…

CYTK key statistics

Explore CYTK's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.